Literature DB >> 19774615

A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection.

Horng-Ren Yang1, Ching-Chuan Hsieh, Lianfu Wang, John J Fung, Lina Lu, Shiguang Qian.   

Abstract

Hepatic stellate cells (HSCs) have demonstrated a strong T-cell inhibitory activity. In a mouse islet transplantation model, cotransplanted HSCs can protect islet allografts from rejection. The involved mechanism is not fully understood. We showed in this study that expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an important apoptosis-inducing ligand, on HSCs was crucial in protection of islet allografts, since HSCs derived from TRAIL knockout mice demonstrated less inhibitory activity towards T-cell proliferative responses, and substantially lost their capacity in protecting cotransplanted islet allografts from rejection, suggesting that TRAIL-mediated T cell apoptotic death is important in HSC-delivered immune regulation activity. 2009 Wiley-Liss, Inc. Microsurgery 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19774615      PMCID: PMC2892209          DOI: 10.1002/micr.20697

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  28 in total

1.  In vivo immune modulatory activity of hepatic stellate cells in mice.

Authors:  Cheng-Hsu Chen; Liang-Mou Kuo; Yigang Chang; Wenhan Wu; Christina Goldbach; Mark A Ross; Donna B Stolz; Liepin Chen; John J Fung; Lin Lu; Shiguang Qian
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

2.  Orthotopic liver transplantation in the mouse.

Authors:  S G Qian; J J Fung; A V Demetris; S T Ildstad; T E Starzl
Journal:  Transplantation       Date:  1991-09       Impact factor: 4.939

3.  The effect of portacaval shunt on delayed-hypersensitivity responses following antigen feeding.

Authors:  M P Callery; T Kamei; M W Flye
Journal:  J Surg Res       Date:  1989-04       Impact factor: 2.192

4.  Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.

Authors:  S Kagawa; C He; J Gu; P Koch; S J Rha; J A Roth; S A Curley; L C Stephens; B Fang
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.

Authors:  Josie Ursini-Siegel; Wenli Zhang; Anne Altmeyer; Eunice N Hatada; Richard K G Do; Hideo Yagita; Selina Chen-Kiang
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis.

Authors:  B Hilliard; A Wilmen; C Seidel; T S Liu; R Göke; Y Chen
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

7.  CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis.

Authors:  Zhongyu Liu; Xin Xu; Hui-Chen Hsu; Albert Tousson; Ping-Ar Yang; Qi Wu; Cunren Liu; Shaohua Yu; Huang-Ge Zhang; John D Mountz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice.

Authors:  Qing-Sheng Mi; Dalam Ly; S-E Lamhamedi-Cherradi; Konstantin V Salojin; Li Zhou; Marsha Grattan; Craig Meagher; Peter Zucker; Youhai H Chen; James Nagle; Dennis Taub; Terry L Delovitch
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

9.  New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells.

Authors:  W Li; C S Kuhr; X X Zheng; K Carper; A W Thomson; J D Reyes; J D Perkins
Journal:  Am J Transplant       Date:  2008-06-12       Impact factor: 8.086

10.  IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression.

Authors:  Su He Wang; Emese Mezosi; Julie M Wolf; Zhengyi Cao; Saho Utsugi; Paul G Gauger; Gerard M Doherty; James R Baker
Journal:  Oncogene       Date:  2004-01-29       Impact factor: 9.867

View more
  8 in total

Review 1.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

Review 2.  Hepatic immune tolerance induced by hepatic stellate cells.

Authors:  Ching-Chuan Hsieh; Chien-Hui Hung; Lina Lu; Shiguang Qian
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 3.  The liver works as a school to educate regulatory immune cells.

Authors:  Fenglei Li; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

Review 4.  Immunological aspects of liver cell transplantation.

Authors:  Felix Oldhafer; Michael Bock; Christine S Falk; Florian W R Vondran
Journal:  World J Transplant       Date:  2016-03-24

5.  Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway.

Authors:  Ronald Charles; Hong-Shiue Chou; Lianfu Wang; John J Fung; Lina Lu; Shiguang Qian
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

Review 6.  The Role of Diverse Liver Cells in Liver Transplantation Tolerance.

Authors:  Yanzhi Jiang; Weitao Que; Ping Zhu; Xiao-Kang Li
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 7.  Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.

Authors:  Naomi Richardson; Sky T H Ng; David C Wraith
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

8.  Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells.

Authors:  D C Oran; T Lokumcu; Y Inceoglu; M B Akolpoglu; O Albayrak; T Bal; M Kurtoglu; M Erkan; F Can; T Bagci-Onder; S Kizilel
Journal:  Mater Today Bio       Date:  2019-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.